Effects of Saxagliptin on Adipose Tissue Inflammation in Humans

Status Completed

Clinical Trial Summary

In this research study, Investigators will be comparing the effects of a medication Saxagliptin versus placebo (a similar looking pill that contains no medication) on inflammation in the body.

Research Hypothesis DPP-4 inhibition by saxagliptin (ONGLYZA™) reduces adipose tissue inflammation in obese individuals and this is characterized by decreases in a) reactive oxygen species (ROS) production, b) toll-like receptors (TLR) and NF-kappa B pathway activation, c) expression of pro-inflammatory genes, d) macrophage infiltration, and e) secretion of pro-inflammatory factors.

Clinical Trial Description

This is a randomized, prospective, double-blind study. Randomization to Saxagliptin and placebo will be in a 2:1 fashion. Treatment duration will be approximately 6 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02285985
Study type	Interventional
Source	Phoenix VA Health Care System
Contact
Status	Completed
Phase	Phase 4
Start date	February 2013
Completion date	October 12, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05102149` - Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus	Phase 3
Withdrawn	`NCT03423355` - Dapagliflozin Effect on Erythropoiesis and Physical Fitness	Phase 4
Terminated	`NCT01923389` - Multiple Dose Study Of PF-05231023 In Obese Adult Subjects	Phase 1
Completed	`NCT02218099` - A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease	Phase 1/Phase 2
Completed	`NCT05607160` - A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes
Completed	`NCT05628090` - A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in India
Completed	`NCT03656744` - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)	Phase 2
Completed	`NCT01002807` - Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State	Phase 1
Recruiting	`NCT04943861` - Human Immunodeficiency Virus (HIV) Food Insecurities	N/A
Completed	`NCT02759107` - A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)	Phase 1
Completed	`NCT02643797` - Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings	Phase 3
Completed	`NCT05294458` - A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects	Phase 1
Recruiting	`NCT06327815` - Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM	Phase 4
Completed	`NCT02219646` - Diabetes & Vardenafil	Phase 2
Recruiting	`NCT05761301` - A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM	Phase 1/Phase 2
Completed	`NCT04504396` - Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy	Phase 3
Completed	`NCT01991093` - Multiple Electrode Aggregometry & Clopidogrel Resistance
Completed	`NCT01871558` - Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin	Phase 3
Completed	`NCT01407003` - Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)	Phase 1/Phase 2
Completed	`NCT01127308` - A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)	Phase 1